NCT07527767已完成不适用
Brain Natriuretic Peptide and Biomarkers of Heart Failure During Sacubitril Valsartan Treatment in Japanese Patients With Chronic Heart Failure and Reduced Ejection Fraction (HFrEF): Secondary Use of PARALLEL-HF Data
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 236
- 试验地点
- 1
- 主要终点
- association between change in NYHA classification and change in plasma log BNP levels from Baseline
研究概览
简要总结
This study utilized the blood and first morning void (FMV) urine samples from the PARALLEL-HF study (core part). The PARALLEL-HF study (core part) was a multicenter, randomized, double-blind, double-dummy, parallel-group, active-controlled study to assess the effect of sacubitril valsartan at a target dose of 200 mg b.i.d. and enalapril 10 mg b.i.d. on cardiovascular (CV) mortality and morbidity in Japanese HF patients with reduced ejection fraction.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 20 Years 至 89 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Written informed consent was required before any assessment could be performed.
- •Male or female outpatients of ≥ 20 years of age (at the time of signing informed consent)
- •Patients with a diagnosis of congestive heart failure NYHA class II-IV and reduced ejection fraction:
- •LVEF ≤ 35% at Visit 1
- •NT-proBNP ≥ 600 pg/mL at Visit 1 OR NT-proBNP ≥ 400 pg/mL at Visit 1 and a hospitalization for HF within the previous 12 months
- •Patients were to be on an angiotensin converting enzyme inhibitor (ACEI) or an angiotensin receptor blocker (ARB) at a stable dose for at least 4 weeks before Visit
- •Patients were to be treated with a β-blocker, unless contraindicated or not tolerated, at a stable dose for at least 4 weeks prior to Visit
- •An aldosterone antagonist was also to be considered in all patients, taking account of renal function, serum potassium and tolerability. If given, the dose of aldosterone antagonist was to be optimized according to guideline recommendations and patient tolerability, and should be stable for at least 4 weeks prior to Visit
- •Other evidence-based therapy for HF was also to be considered e.g., cardiac resynchronization therapy and an implantable cardioverter-defibrillator in selected patients, as recommended by guidelines.
排除标准
- •History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes, ACEIs, ARBs, neutral endopeptidase (NEP) inhibitors as well as known or suspected contraindications to the study drugs.
- •Previous documented history of intolerance to ACEIs or ARBs.
- •Known history of angioedema.
- •Requirement of treatment with both ACEIs and ARBs.
- •Current acute decompensated HF (exacerbation of chronic HF manifested by signs and symptoms that may require intravenous therapy).
- •Symptomatic hypotension and/or a systolic blood pressure (SBP) < 100 mmHg at Visit 1 (Screening) or < 95 mmHg at Visit 199 (end of run-in).
- •Estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m2 as measured by the Japanese formula at Visit 1 (Screening) or Visit 199 (end of run-in) or > 35% decline in eGFR between Visit 1 and Visit 199 (according to local measurements).
- •Serum potassium > 5.2 mmol/L (mEq/L) at Visit 1 (Screening) or > 5.4 mmol/L (mEq/L) at Visit 199 (end of run-in) (according to local measurements).
- •Acute coronary syndrome, stroke, transient ischemic attack, cardiac, carotid or other major CV surgery, percutaneous coronary intervention (PCI) or carotid angioplasty within the 3 months prior to Visit
- •Coronary or carotid artery disease likely to require surgical or percutaneous intervention within the 6 months after Visit
- •Implantation of a cardiac resynchronization therapy pacemaker (CRT-P) or a cardiac resynchronization therapy defibrillator (CRT-D) or upgrading of an existing conventional pacemaker or an implantable cardioverter defibrillator (ICD) to CRT device within 3 months prior to Visit 1 or intent to implant such a device. Also, patients who had implantation of a conventional pacemaker or an ICD or had a revision of a pacemaker or other device leads within 1 month before Visit 1 are excluded.
- •History of severe pulmonary disease.
结局指标
主要结局
association between change in NYHA classification and change in plasma log BNP levels from Baseline
时间窗: Baseline, Month 6, Week 0, Week 4 and Week 8
In this study, response variable change from Baseline in NYHA class was grouped into 3 categories: improved=3 unchanged=2 and worsened=1. An ordinal logistic regression model was used to assess the relationship between change from Baseline in NYHA classification and log-transformed change from Baseline of (BNP).
次要结局
- association between the change in NYHA classification and log-transformed biomarkers from Baseline to pre-defined time points in patients treated with either sacubitril valsartan or enalapril(Week 0, Week 4, Week 8, Month 6)
- association between the change in KCCQ-CSS and log-transformed biomarkers from Baseline to pre-defined time points in patients treated with either sacubitril valsartan or enalapril(Week 0, Week 4, Week 8, Month 6)
- association between the change in NYHA classification from Baseline to pre-defined time points and Baseline of log-transformed biomarkers in patients treated with either sacubitril valsartan or enalapril.(Week 0, Week 4, Week 8, Month 6)
- association between the change in KCCQ from Baseline to pre-defined time points and Baseline of log-transformed biomarkers in patients treated with either sacubitril valsartan or enalapril.(Week 0, Week 4, Week 8, Month 6)
- change in log-transformed biomarkers from baseline to pre-defined time points(Week 0, Week 4, Week 8, Month 6)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
不适用
脑钠肽前体（BNP）与全心舒张末容积指数（GEDVI）的相关性ChiCTR-OCH-11001332自筹50
尚未招募
不适用
Evaluation of NT-ProBNP marker to predict the cardiovascular risk in individuals with type 2 diabetes.CTRI/2023/12/060795Roche Diagnostics302
尚未招募
不适用
Role of B-Type Natriuretic Peptide in predicting in Hospital mortality and Length of stay of Acute Exacerbation of Chronic Obstructive Pulmonary Disease Cases with Normal Heart functionCTRI/2024/12/077810Department of Critical Care Medicine90
Unknown
不适用
脑钠肽在慢性左心衰患者预后评价中的应用价值ChiCTR2500101966自筹
招募中
不适用
Spot Analysis of Natriuresis to Guide up- or Down-titration of Diuretic Therapy in Ambulatory Patients With Chronic Heart FailureHeart FailureNCT07369856Cardiology Research UBC300